Trial site
National Neuromuscular Research Institute
Austin, Texas 78759, United StatesNot linked to an institution yet
- 11running trials
- 3closed trials
The trials here
What the 14 trials at this site are about, from their registry records.
- Phase
- Phase 26 trials
- Phase 35 trials
- Phase 41 trial
- Status
- Recruiting7 trials
- Active, not recruiting3 trials
- Completed2 trials
- Enrolling by invitation1 trial
- Terminated1 trial
- Lead sponsor
- argenx8 trials
- Edgewise Therapeutics, Inc.2 trials
- Cartesian Therapeutics1 trial
- Eidos Therapeutics, a BridgeBio company1 trial
- New England Cell Therapeutics, Inc.1 trial
- and 1 more
Running trials
Recruiting
ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis
NCT07673627· Phase 2· argenx· Source
Contact: Yessar Hussain, MD
Recruiting
Descartes-08 in Autoantibody Myositis
NCT07391605· Phase 2· Cartesian Therapeutics· Source
Contact: Cartesian Therapeutics
Recruiting
ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod
NCT07284420· Phase 2· argenx· Source
Contact: Yessar Hussain, MD
Recruiting
ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis
NCT07294170· argenx· Source
Contact: Yessar Hussain, MD
Recruiting
A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP
NCT07091630· Phase 3· argenx· Source
Contact: Yessar Hussain, MD
Recruiting
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
NCT06563895· Phase 3· Eidos Therapeutics, a BridgeBio company· Source
Recruiting
A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa
NCT06298565· argenx· Source
Contact: Yessar Hussain, MD
Active, not recruiting
A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis
NCT06558279· Phase 3· argenx· Source
Active, not recruiting
A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis
NCT06298552· Phase 3· argenx· Source
Enrolling by invitation
Open-Label Extension of EDG-5506 in Participants With Becker Muscular Dystrophy
NCT06066580· Phase 2· Edgewise Therapeutics, Inc.· Source
Active, not recruiting
A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis
NCT05070858· Phase 3· Regeneron Pharmaceuticals· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error